<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00831623</url>
  </required_header>
  <id_info>
    <org_study_id>58116</org_study_id>
    <nct_id>NCT00831623</nct_id>
  </id_info>
  <brief_title>Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer</brief_title>
  <official_title>Phase I-II Trial of Hypofractionated Conformal Proton Beam Radiation Therapy for Favorable-risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine hypofractionated conformal proton beam radiation
      therapy of prostate cancer can achieve similar treatment benefits as our current
      institutional standard with conventional fractionation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiation therapy has a long and established role in the curative treatment of organ-confined
      prostate cancer. However, the optimal radiation dose and treatment schedule remain unknown.
      The use of hypofractionation has a long and generally successful history in conformal proton
      beam therapy. Several reports detailing the efficacy and safety of hypofractionated conformal
      radiation therapy (with x-rays) of prostate cancer can be found in the literature.
      Hypofractionated conformal proton beam radiation therapy has become our institutional routine
      for the treatment of numerous solid tumors. The purpose of this study is to determine if a
      shortened overall treatment schedule will result in equivalent tumor control rates and no
      increased side effects as compared to our current institutional standard treatment of an
      equivalent dose given over a longer period of time.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related morbidity</measure>
    <time_frame>yearly update greater than 20 years</time_frame>
    <description>To determine if late Radiation Therapy Oncology Group (RTOG) &gt;/= to Grade 3 treatment-related morbidity, which is no worse than that engendered by our current institutional standard with conventional fractionation, can be maintained in a hypofractionated schedule</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the incidence of acute and late Gastrointestinal and To determine the incidence of acute and late gastrointestinal and genitourinary morbidity</measure>
    <time_frame>yearly update greater than 20 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Proton radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Radiation</intervention_name>
    <description>3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)</description>
    <arm_group_label>Proton radiation therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton</intervention_name>
    <description>As above</description>
    <arm_group_label>Proton radiation therapy</arm_group_label>
    <other_name>Proton Radiation treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma within 180 days of registration

          -  History &amp; Physical Exam, including digital rectal exam (DRE), within 8 wks prior to
             registration

          -  Histologic evaluation of prostate biopsies at LLUMC, with Gleason score assignment

          -  Clinical stage, Tumor Stage (T1-T2C)

          -  Prostatic Specific Angigen (PSA) less than 10 ng.ml within 180 days prior to
             registration

        Exclusion Criteria:

          -  Prior or concurrent invasive malignancy

          -  Evidence of distant metastasis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry D Slater, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University Medical Center Dept. of Radiation Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>*Jerry D Slater/Judy Hansen *PI</last_name>
    <phone>909-558-4258</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brooke Lawson, RN</last_name>
    <phone>1 800 496-4966</phone>
    <email>blawson@llu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loma Linda University Medical Center / James M. Slater Proton Treatment Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry D Slater, MD</last_name>
      <phone>909-558-4258</phone>
      <email>jdslater@llu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Proton Referral Office, RN</last_name>
      <phone>1 800 496-4966</phone>
      <phone_ext>Back-up</phone_ext>
      <email>scteichm@llu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jerry D Slater</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005 Sep 14;294(10):1233-9. Erratum in: JAMA. 2008 Feb 27;299(8):899-900.</citation>
    <PMID>16160131</PMID>
  </reference>
  <reference>
    <citation>Rossi CJ Jr, Slater JD, Yonemoto LT, Jabola BR, Bush DA, Levy RP, Grove R, Slater JM. Influence of patient age on biochemical freedom from disease in patients undergoing conformal proton radiotherapy of organ-confined prostate cancer. Urology. 2004 Oct;64(4):729-32.</citation>
    <PMID>15491710</PMID>
  </reference>
  <reference>
    <citation>Slater JD, Rossi CJ Jr, Yonemoto LT, Bush DA, Jabola BR, Levy RP, Grove RI, Preston W, Slater JM. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):348-52.</citation>
    <PMID>15145147</PMID>
  </reference>
  <reference>
    <citation>Slater JM, Bush DA, Grove R, Slater JD. The prognostic value of percentage of positive biopsy cores, percentage of cancer volume, and maximum involvement of biopsy cores in prostate cancer patients receiving proton and photon beam therapy. Technol Cancer Res Treat. 2014 Jun;13(3):227-31. doi: 10.7785/tcrtexpress.2013.600271. Epub 2013 Sep 20.</citation>
    <PMID>24066950</PMID>
  </reference>
  <reference>
    <citation>Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, Rossi CJ. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1005-9. doi: 10.1016/j.ijrobp.2010.06.047. Epub 2010 Oct 6.</citation>
    <PMID>20932675</PMID>
  </reference>
  <reference>
    <citation>Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, Zietman AL. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA. 2010 Mar 17;303(11):1046-53. doi: 10.1001/jama.2010.287. Erratum in: JAMA. 2010 Apr 7;303(13):1257.</citation>
    <PMID>20233822</PMID>
  </reference>
  <reference>
    <citation>Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010 Mar 1;28(7):1106-11. doi: 10.1200/JCO.2009.25.8475. Epub 2010 Feb 1.</citation>
    <PMID>20124169</PMID>
  </reference>
  <reference>
    <citation>Slater JD. Clinical applications of proton radiation treatment at Loma Linda University: review of a fifteen-year experience. Technol Cancer Res Treat. 2006 Apr;5(2):81-9. Review.</citation>
    <PMID>16551128</PMID>
  </reference>
  <reference>
    <citation>Ronson BB, Yonemoto LT, Rossi CJ, Slater JM, Slater JD. Patient tolerance of rectal balloons in conformal radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1367-70. Epub 2006 Feb 20.</citation>
    <PMID>16488552</PMID>
  </reference>
  <reference>
    <citation>Slater JD, Rossi CJ Jr, Yonemoto LT, Reyes-Molyneux NJ, Bush DA, Antoine JE, Miller DW, Teichman SL, Slater JM. Conformal proton therapy for early-stage prostate cancer. Urology. 1999 May;53(5):978-84.</citation>
    <PMID>10223493</PMID>
  </reference>
  <reference>
    <citation>Slater JD, Yonemoto LT, Rossi CJ Jr, Reyes-Molyneux NJ, Bush DA, Antoine JE, Loredo LN, Schulte RW, Teichman SL, Slater JM. Conformal proton therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):299-304.</citation>
    <PMID>9788407</PMID>
  </reference>
  <reference>
    <citation>Slater JD. Twenty years of proton radiation therapy at Loma Linda University Medical Center. In U. Linz, editor. Ion beam therapy: fundamentals, technology, clinical applications. Berlin: Springer, 2012:581-595.</citation>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2009</study_first_submitted>
  <study_first_submitted_qc>January 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2009</study_first_posted>
  <last_update_submitted>April 15, 2018</last_update_submitted>
  <last_update_submitted_qc>April 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Jerry D. Slater, MD</investigator_full_name>
    <investigator_title>Professor and Chair Department of Radiation Medicine</investigator_title>
  </responsible_party>
  <keyword>hypofractionation</keyword>
  <keyword>proton beam radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

